Abstract Library

#4661 Comparison of preoperative chemotherapy and radio ligand therapy on prognosis after surgical resection for locally advanced or hepatic metastatic pancreatic neuroendocrine tumours

Introduction: The role of preoperative treatments in improving the rate of radical resection and survival of either locally advanced (LA) or hepatic metastatic (HM) pancreatic neuroendocrine tumours (panNETs) is unclear.

Conference:

Presenting Author:

Authors: Provinciali L, de Mestier L, Pontillo D, Guarneri G, Partelli S,

Keywords: adjuvant therapy, chemotherapy, event free survival, liver transplantation, RadioLigand Therapy,

#4641 Case series: Tuberous sclerosis associated pancreatic neuroendocrine tumours at a tertiary centre

Introduction: Tuberous sclerosis (TSC) is an autosomal dominant condition which can increase the risk of pancreatic neuroendocrine tumours (PanNETs) (1). Patients with TSC undergo screening for renal tumours which may include pancreatic imaging (2). There are currently no screening guidelines for PanNETs in patients with TSC.

Conference:

Presenting Author: Frydman A

Authors: Frydman A, Clement D, Srirajaskanthan R,

Keywords: Pancreas neuroendocrine tumour, Tuberous sclerosis,

#4632 MEN1 associated pancreatic neuroendocrine tumours: Re-evaluating the 2cm cut-off for surgical resection

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are the leading cause of death in patients (pts) with MEN1. Screening is recommended to diagnose early and prevent metastases. The optimal cut-off of when to intervene in a PanNET is still an area of debate.

Conference:

Presenting Author: Frydman A

Authors: Frydman A, Clement D, Srirajaskanthan R,

Keywords: MEN1, Pan NET,

#4622 Elucidating the role of high mobility group box 3 (Hmgb3) during progression and response to radiation therapy in pancreatic neuroendocrine tumours

Introduction: We have recently demonstrated that HMGB3 is upregulated during the pancreatic neuroendocrine tumours (PanNETs) transition via dedifferentiation from a relatively benign molecular subtype to an aggressive and highly metastatic molecular subtype. HMGB3 expression has recently been linked to resistance to therapy, metastasis, and poor prognosis in patients with various solid cancers.

Conference:

Presenting Author: Kulathunga N

Authors: Kulathunga N, Wang Z, Qureshi A, Lok B, Tyryshkin K,

Keywords: pancreatic neuroendocrine tumour, HMGB3, tumour progression,

#4620 Impact of the extent of surgical resection on the development of post-operative diabetes in patients undergoing distal pancreatectomy for non-functioning pancreatic neuroendocrine tumours (NF-PanNET)

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are often indolent neoplasms. Surgery is the primary curative approach for localised non-functioning (NF) PanNETs, but it poses a risk of long-term complications, such as diabetes, impacting quality of life.

Conference:

Presenting Author:

Authors: Battistella A, Partelli S, Guccinelli E, Prato F, Andreasi V,

Keywords: Pan NET, distal pancreatectomy, post-operative diabetes, surgical extension,